The medial division of the central nucleus of the amygdala (CeA M ) and the lateral division of the bed nucleus of the stria terminalis (BNST L ) are closely related. Both receive projections from the basolateral amygdala (BLA) and both project to brain areas that mediate fear-influenced behaviors. In contrast to CeA M however, initial attempts to implicate the BNST in conditioned fear responses were largely unsuccessful. More recent studies have shown that the BNST does participate in some types of anxiety and stress responses. Here, we review evidence suggesting that the CeA M and BNST L are functionally complementary, with CeA M mediating short-but not long-duration threat responses (i.e., phasic fear) and BNST L mediating long-but not shortduration responses (sustained fear or 'anxiety'). We also review findings implicating the stress-related peptide corticotropin-releasing factor (CRF) in sustained but not phasic threat responses, and attempt to integrate these findings into a neural circuit model which accounts for these and related observations. © 2009 Elsevier Inc. All rights reserved.
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A now-familiar and widely-adopted neural circuit model of fear places the amygdala in center stage and assigns different functions to different amygdala subdivisions (Fig. 1) . Thus, the basolateral amygdala (BLA) screens incoming sensory information for threat cues and, if such cues are detected, passes this information on to the central nucleus of the amygdala's medial subdivision (CeA M ), which mediates threat responses by way of its many projections to areas that mediate specific fear-influenced behaviors (c.f., Davis, 1992; Fanselow and LeDoux, 1999; Maren, 2001; Pare et al., 2004) .
In the following pages, we review evidence suggesting that this model is incomplete, and should be expanded to include the bed nucleus of the stria terminalis (specifically, it's lateral subdivision -BNST L ). In fact, by many criteria, the CeA and BNST are closely related (Alheid et al., 1995; Alheid and Heimer, 1988; Johnston, 1923) . Of particular interest, both receive projections from the BLA (c.f., Dong et al., 2001a; Pitkanen, 2000) and project in turn to many of the same brain areas that mediate fear-associated behaviors (e.g., Gray and Magnuson, 1987, 1992; Holstege et al., 1985; Hopkins and Holstege, 1978; Peyron et al., 1998; Rosen et al., 1991; Schmued, 1994; Schwaber et al., 1982) . Although these similarities have been appreciated for some time, early lesion studies found no evidence for an involvement of the BNST in several fear-associated behaviors including freezing and blood pressure changes to 10-or 120-s presentations of an auditory CS (LeDoux et al., 1988) , or fear-potentiated startle to 3.7-s presentations Abbreviation: α-helical CRF 9-41 , a peptide CRF receptor antagonist; α2, alpha-2 -a type of norepinephrine receptor; αhCRF, same as a-helical CRF 9-41 -a peptide CRF receptor antagonist; μg, micrograms; μM, micromolar; 6-OHDA, 6-hydroxydopamine -destroys dopamine and norepinephrine cells; ACTH, adrenocorticotropic hormone; AMPA, α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate -a type of glutamate receptor; AP5, amino-5-phosphonovaleric acid -blocks a type of glutamate receptor called the N-methyl-Daspartate receptor; BLA, basolateral amygdala (includes lateral, basal and basomedial nuclei); BNST, bed nucleus of the stria terminalis; BNST L , lateral division of the bed nucleus of the stria terminalis; BNST M , medial division of the bed nucleus of the stria terminalis; c.f., consult other references; CeA, central nucleus of the amygdala; CeA L , lateral division of the central nucleus of the amygdala; CeA M , medial division of the central nucleus of the amygdala; chloro-APB, (±)-6-Chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide -dopamine type 1 receptor receptor agonist; CNS, central nervous system; CoCl 2 , cobalt chloride -blocks neurotransmitter release; CRF-R1, corticotropin releasing factor type 1 receptor; CRF-R2, corticotropin releasing factor type 2 receptor; CRF, corticotropin releasing factor same as CRH -corticotropin releasing hormone; CS, conditioned stimulus; D-Phe CRF 12-41 , a peptide CRF antagonist; D1, dopamine types 1 receptor; dB, decibel; EtOH, ethanol; fMRI, functional magnetic resonance imaging; Fos, a gene that is transcribed rapidly when certain neurons depolarize; GABA-A, a fast acting GABA receptor type; GABA, γ-Aminobutyric acid -an inhibitor neurotransmitter; GSK876008, a non-peptide CRF receptor antagonist; Hz, Hertz = cycles per second; ICI 118,551, blocks a type of norepinephrine receptor called the Beta 2 adrenergic receptor; ISI, interstimulus interval; Kv4.2, a particular subunit of the potassium channel; mA, milliampere; mg/kg, milligrams per kilogram; mRNA, messenger ribonucleic acid; NBQX, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione -a glutamate receptor antagonist -primarily an AMPA antagonist; NMDA, N-methyl-D-aspartate, a type of glutamate receptor; PTSD, posttraumatic stress disorder; SCH 23390, dopamine type 1 receptor; SSRI, serotonin selective reuptake inhibitor; TTX, tetrodotoxin -a toxin that blocks sodium channels and hence action potentials in cells and axons; U, Mann-Whitney test between two groups (non-parametric); US, unconditioned stimulus. 
